In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats

British Journal of Pharmacology

Volumn 132, Issue 8, 2001, Pages 1683-1690

  Kugelberg, Fredrik C ^a   Apelqvist, Gustav ^b   Carlsson, Björn ^a   Ahlner, Johan ^a,c   Bengtsson, Finn ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c National Board of Forensic Medicine   (Sweden)

Author keywords

Citalopram; Enantioselective drug analysis; Open field behaviour; Pharmacokinetics; Toxic dose

Indexed keywords

CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EXPOSURE; ENANTIOMER; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0035047361     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704015     Document Type: Article

References (37)

1. Contemporary management of depression
2. Central vs peripheral spontaneous behavioral abnormalities in experimental hepatic encephalopathy
3. Diurnal and gender effects by chronic portacaval shunting in rats on spontaneous locomotor and rearing activities in an open-field
4. The impact of time after portacaval shunt in the rat on behavior, brain serotonin, and brain and muscle histology
5. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels
6. The importance of new antidepressants in the treatment of anxiety/depressive disorders
7. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications
8. Solid-phase extraction with end-capped C2 columns for the routine measurement of racemic citalopram and metabolites in plasma by high-performance liquid chromatography
9. Optimisation and characterisation of the chiral separation of citalopram and its demethylated metabolites by response surface methodology
10. Acute toxicity profile of maprotiline in the rat
11. Stereoselective drug disposition: Potential for misinterpretation of drug disposition data
12. Plasma levels of citalopram enantiomers and metabolites in elderly patients
13. Kinetics of citalopram in test animals; drug exposure in safety studies
14. Kinetics of citalopram in man; plasma levels in patients
15. The pharmacokinetic and safety evaluation of citalopram from preclinical and clinical data
16. Symptoms and signs of severe citalopram overdose
17. Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171
18. The pharmacology of citalopram
19. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer
20. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram
21. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects
22. Distribution of citalopram in the blood serum and in the central nervous system of rats after single and multiple dosage
23. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes
24. Fatal overdose with citalopram
25. Citalopram overdose-review of cases treated in Swedish hospitals
26. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine
27. Xenobiotic metabolism in brain
28. Clinical overview of serotonin reuptake inhibitors
29. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography
30. Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC
31. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium
32. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans
33. Cytochrome P-450 activities in human and rat brain microsomes
34. Regional distribution of cytochrome P-450 in the rat brain: Spectral quantitation and contribution of P-450b,e, and P-450c,d
35. Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats
36. Citalopram concentrations in samples from autopsies and living persons
37. Stereoselective HPLC-assay for citalopram and its metabolites